Indian J Pharm Close
 

Figure 3 :Kaplan–Meier graph showing survival patterns for various parameters as mentioned below. X-axis represents time duration in months and Y-axis represents cumulative disease-free survival (DFS) percentage. (A) ErbB-2 status and DFS. Total number of cases - 179; ErbB-2 positive - 84; ErbB-2 negative - 95 (B) Lymphnode (LN) status and DFS. Total number of cases - 176; LN negative - 63; LNs involved - 113 (C) Stage of the disease and DFS. Total number of cases - 173; Stage 1 - 19; Stage 2 - 82; Stage 3 - 33; Stage 4 - 39 (D) Distant metastasis and DFS. Total number of cases - 167; distant metastasis present - 18; distant metastasis absent - 149. Combined ErbB-2 and LN status and DFS. Total cases - 171; ErbB-2 +ve/LN +ve - 60; ErbB-2 +ve/LN -ve - 21; ErbB-2 -ve/LN +ve - 52; ErbB-2 -ve/LN -ve - 38

Figure 3 :Kaplan–Meier graph showing survival patterns for various parameters as mentioned below. X-axis represents time duration in months and Y-axis represents cumulative disease-free survival (DFS) percentage. (A) ErbB-2 status and DFS. Total number of cases - 179; ErbB-2 positive - 84; ErbB-2 negative - 95 (B) Lymphnode (LN) status and DFS. Total number of cases - 176; LN negative - 63; LNs involved -
113 (C) Stage of the disease and DFS. Total number of cases - 173; Stage 1 - 19; Stage 2 - 82; Stage 3 - 33; Stage 4 - 39 (D) Distant metastasis and DFS. Total number of cases - 167; distant metastasis present - 18; distant metastasis absent - 149. Combined ErbB-2 and LN status and DFS. Total cases - 171; ErbB-2 +ve/LN +ve - 60; ErbB-2 +ve/LN -ve - 21; ErbB-2 -ve/LN +ve - 52; ErbB-2 -ve/LN -ve - 38